Optimal duration of treatment with eculizumab in atypical hemolytic uremic syndrome (aHUS)-a question to be addressed in a scientific way

Pediatr Nephrol. 2019 May;34(5):943-949. doi: 10.1007/s00467-019-4192-7. Epub 2019 Jan 28.

Author

Affiliation

¹ Pediatric Nephrology, Hospital Universitari Vall d' Hebron, Universitat Autonoma de Barcelona, Barcelona, Spain. gariceta@vhebron.net.

PMID: 30693384
DOI: 10.1007/s00467-019-4192-7

No abstract available

Publication types

Editorial

MeSH terms

Antibodies, Monoclonal, Humanized / administration & dosage*
Atypical Hemolytic Uremic Syndrome / complications
Atypical Hemolytic Uremic Syndrome / diagnosis
Atypical Hemolytic Uremic Syndrome / drug therapy*
Atypical Hemolytic Uremic Syndrome / mortality
Child
Complement Inactivating Agents / administration & dosage*
Disease-Free Survival
Dose-Response Relationship, Drug
Drug Administration Schedule
Duration of Therapy*
Humans
Kidney Failure, Chronic / epidemiology*
Kidney Failure, Chronic / etiology
Kidney Failure, Chronic / prevention & control
Time Factors
Treatment Outcome

Substances

Antibodies, Monoclonal, Humanized
Complement Inactivating Agents
eculizumab